Cipargamin

Novartis 

Product vision
  • Part of single-exposure radical cure

  • Potential for use in severe malaria

MoA
  • PfATP4 inhibitor

     

Key features
  • First validated new molecular target in 20 years; very rapid killing of parasites

  • 75mg human dose stays above Minimal Parasiticidal Concentration for >8 days

  • Potential for transmission-blocking activitiy in a Standard Membrane Feeding Assay

Challenges
  • Safety profile to be further characterized in malaria patient study

Status
  • Phase II study in patients started in February 2018 

  • Parenteral GLP safety study in progress

Next milestone
  • Phase II study completion 

  • Initiate parenteral First In Human study 

Previously
  • Names NITD609, KAE609: discovery partnership with Wellcome Trust, Novartis, and the Swiss Tropical and Public Health Institute

MMV Project Director
  • Dr Gonzalo Acuña